Screener
Regenxbio RGNX R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 108,019 | 21,359 | 114,412 | 110,371 |
| Operating Expenses | ||||
| Cost of license and royalty revenues | 1,042 | 5,209 | 12,116 | 8,645 |
| Research and development | 56,086 | 59,500 | 113,425 | 112,587 |
| General and administrative | 21,616 | 19,883 | 42,922 | 40,230 |
| Other operating expenses | 12 | 45 | 48 | 60 |
| Total operating expenses | 78,756 | 84,637 | 168,511 | 161,522 |
| Income (loss) from operations | 29,263 | (63,278) | (54,099) | (51,151) |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's R&D?
- Regenxbio (RGNX) reported R&D of $56.09M in Q2 2026.
- How has Regenxbio's R&D changed year-over-year?
- Regenxbio's R&D decreased by 5.7% year-over-year, from $59.5M to $56.09M.
- What is the long-term trend for Regenxbio's R&D?
- Over 4 years (2021 to 2025), Regenxbio's R&D has grown at a 5.9% compound annual growth rate (CAGR), from $181.44M to $228.3M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Regenxbio's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude